Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study).

Angioplasty Coronary artery disease Drug-coated balloon Drug-eluting stent Patient outcome assessment Percutaneous coronary intervention

Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 07 04 2022
accepted: 13 06 2022
medline: 25 8 2023
pubmed: 2 7 2022
entrez: 1 7 2022
Statut: ppublish

Résumé

We evaluated a decision algorithm for percutaneous coronary interventions (PCI) based on a no-stent strategy, corresponding to a combination of scoring balloon angioplasty (SCBA) and drug-coated balloon (DCB), as a first line approach. Stents were used only in unstable patients, or in case of mandatory bailout stenting (BO-stent). From April 2019 to March 2020, 984 consecutive patients, including 1922 lesions, underwent PCI. The 12-month primary end-point was a composite of major adverse cardiac events (MACE) defined as all-cause death, nonfatal myocardial infarction, nonfatal stroke, and target lesion revascularization. Patients were classified into conventional or no-stent strategy groups according to the PCI strategy. In the no-stent strategy group, they were further classified into BO-stent or DCB-only groups. Their metal index was calculated by stent length divided by the total lesion length. The no-stent strategy was applied in 85% of the patients, and it was successful for 65% of them. MACE occurred in 7.1% of the study population, including 4.2% of all-cause death. Target lesion revascularization was required in 1.4%, 3.6%, and 1.5% of patients in the conventional DES, BO-stent, and DCB-only groups, respectively. MACE occurred more often in the elderly and in those treated with at least one stent (metal index greater than 0). The no-stent strategy, i.e., revascularization of coronary lesions by SCBA followed by DCB and with DES bailout stenting, was effective and safe at 1 year. This PCI approach was applicable on a daily practice in our cath lab. This study was registered with clinicaltrials.gov (NCT03893396, first posted on March 28, 2019). Feasibility, safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease. DES: drug eluting stent; SCBA: scoring balloon angioplasty; BO-stent: at least one stent; DCB: drug coated balloon; BMS: bare metal stent; Bailout (dash lines); MACE: major adverse cardiac event.

Identifiants

pubmed: 35776144
doi: 10.1007/s00392-022-02054-7
pii: 10.1007/s00392-022-02054-7
pmc: PMC10449686
doi:

Banques de données

ClinicalTrials.gov
['NCT03893396']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1164-1174

Subventions

Organisme : Groupe Hospitalier de la Rochelle Ré Aunis
ID : 2018P02283
Organisme : B Braun Paris (FR)
ID : L-FR-2019-0184/MEDAG-19-00166

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

JAMA Netw Open. 2020 Aug 3;3(8):e2012546
pubmed: 32756926
J Interv Cardiol. 2017 Apr;30(2):139-146
pubmed: 28116778
Am J Cardiol. 1991 Aug 15;68(5):467-71
pubmed: 1872273
JACC Cardiovasc Interv. 2022 Apr 11;15(7):770-779
pubmed: 35305906
Lancet. 2018 Sep 8;392(10150):849-856
pubmed: 30170854
J Am Coll Cardiol. 2020 Mar 10;75(9):1017-1028
pubmed: 32138961
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402
pubmed: 32473887
JACC Cardiovasc Interv. 2019 Aug 12;12(15):1465-1478
pubmed: 31395217
Lancet. 2019 Jul 20;394(10194):230-239
pubmed: 31204115
Lancet. 2020 Nov 7;396(10261):1504-1510
pubmed: 33091360
Adv Ther. 2020 May;37(5):2210-2223
pubmed: 32274746
Lancet. 1978 Feb 4;1(8058):263
pubmed: 74678
Circulation. 2007 Aug 21;116(8):961-8
pubmed: 17709651
Clin Res Cardiol. 2022 Jul;111(7):732-741
pubmed: 34313800
Circ Cardiovasc Interv. 2019 Oct;12(10):e008434
pubmed: 31553205
J Am Coll Cardiol. 2017 Feb 14;69(6):616-624
pubmed: 28183505
Catheter Cardiovasc Interv. 2017 Nov 15;90(6):890-897
pubmed: 28544186
Am J Cardiol. 2016 Oct 15;118(8):1178-1186
pubmed: 27569387
Catheter Cardiovasc Interv. 2019 Feb 1;93(2):181-188
pubmed: 30280482
EuroIntervention. 2020 Apr 17;15(17):1527-1533
pubmed: 31659986
Heart Views. 2019 Jul-Sep;20(3):101-108
pubmed: 31620255
EuroIntervention. 2022 Mar 18;17(16):1330-1339
pubmed: 34881696
Circulation. 2020 Aug 11;142(6):538-545
pubmed: 32551860
Cardiovasc Interv Ther. 2019 Oct;34(4):317-324
pubmed: 30652250
Cardiol J. 2021;28(1):136-149
pubmed: 31565793
Eur Heart J. 2014 Oct 1;35(37):2541-619
pubmed: 25173339
Eur Heart J Suppl. 2021 Oct 08;23(Suppl E):E63-E67
pubmed: 34650357
J Mech Behav Biomed Mater. 2020 Sep;109:103836
pubmed: 32543402
EuroIntervention. 2021 Mar 19;16(16):1307-1317
pubmed: 33074152

Auteurs

Ludovic Meunier (L)

Cardiology Department, Centre Hospitalier La Rochelle, La Rochelle, France.

Matthieu Godin (M)

Cardiology Department, Clinique St-Hilaire, Rouen, France.

Géraud Souteyrand (G)

Département de Cardiologie, CHU Clermont-Ferrand, ISIT, CaVITI, CNRS (UMR-6284), Université d'Auvergne, Clermont-Ferrand, France.

Benoît Mottin (B)

Cardiology Department, Centre Hospitalier La Rochelle, La Rochelle, France.

Yann Valy (Y)

Cardiology Department, Centre Hospitalier La Rochelle, La Rochelle, France.

Vincent Lordet (V)

Cardiology Department, Centre Hospitalier La Rochelle, La Rochelle, France.

Christian Benoit (C)

Cardiology Department, Centre Hospitalier La Rochelle, La Rochelle, France.

Ronan Bakdi (R)

Cardiology Department, Centre Hospitalier La Rochelle, La Rochelle, France.

Virginie Laurençon (V)

Clinical Trials Unit, Centre Hospitalier La Rochelle, La Rochelle, France.

Philippe Genereux (P)

Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA.
Morristown Medical Center, Gagnon Cardiovascular Institute, Morristown, NJ, USA.

Matthias Waliszewski (M)

Medical Scientific Affairs, B.Braun Melsungen AG, Berlin, Germany.
Department of Internal Medicine and Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany.

Caroline Allix-Béguec (C)

Clinical Trials Unit, Centre Hospitalier La Rochelle, La Rochelle, France. caroline.allix-beguec@ght-atlantique17.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH